Randomized, open-label, phase II, biomarker study of immune-mediated mechanism of action of neoadjuvant subcutaneous trastuzumab in patients with locally advanced, inflammatory, or early HER2-positive breast cancer—Immun-HER trial (GOIRC-01-2016)Benedetta Pellegrino, Antonino Musolino, Elisabetta Cretella et al.|Journal for ImmunoTherapy of Cancer|2023Cited by 10
Prognostic impact of interval breast cancer detection in women with pT1a N0M0 breast cancer with HER2-positive status: Results from a multicentre population-based cancer registry studyAntonino Musolino, Maria Michiara, Fabio Falcini et al.|European Journal of Cancer|2017Cited by 3